Check out IPXL, Generic at $25 with proprietary Parkinsons drug to be approved in Jan. Maybe PFE should buy them?
If you are seeking an opportunity I would reccomend Impax pharma IPXL at $25. They have Rytary a phase 3 drug for Parkinsons that should get approval in mid January. They have a pact with Glaxo for the Intl marketing of the drug and Glaxo will pay IPXL $175 mil upon approval. This will be a lead drug for Parkinsons with the least side affects.
IPXL has $355 Mil in cash, no debt and should have a robust earnings report. They are an authorized generic with Astra Z for a big rev generating drug that will be highly profitable.
Bottom line one of the few independent generics at a reasonable price with strong proprietary drugs. One will be approved in Jan and another by mid 2013 with good prospects.
Check it out, I think it will rise to the $40's quickly barring a buyout by Teva or a large pharma that wants the Parkinsons market.